

MAY 16 2006

Cooley Godward LLP**FAX**

THIS FACSIMILE AND THE INFORMATION IT CONTAINS ARE INTENDED TO BE A CONFIDENTIAL COMMUNICATION ONLY TO THE PERSON OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE NOTIFY US BY TELEPHONE AND RETURN THIS ORIGINAL FAX TO THIS OFFICE BY MAIL.

ATTORNEYS AT LAW

The Bowen Building
875 15th Street NW
Suite 800
Washington, DC
20005-2221

MAIN (202) 842-7800
FAX (202) 842-7899

Offices:
Broomfield, CO
Palo Alto, CA
Reston, VA
San Diego, CA
San Francisco, CA
Washington, DC

DATE: May 16, 2006

PLEASE DELIVER TO:	FAX No.:
U.S. Patent and Trademark Office	571-273-8300

FROM: Heather M. Boussios

PHONE: (202) 842-7846

REPLY FAX: (202) 842-7800

RE:

NUMBER OF PAGES, INCLUDING COVER PAGE: 4	Client Number: SOPH-002/02US (306561-2011)
	Requestor #: 13262

MESSAGE:

Re: U.S. Patent Application No. 10/091,724

**RECEIVED
CENTRAL FAX CENTER****MAY 16 2006****Attorney Docket No. SOPH-002/02US****PATENT**

I hereby certify that this correspondence is being transmitted by facsimile to the USPTO, Facsimile Number 571-273-0747, at United States Patent and Trademark Office, Alexandria, VA 22314, on May 16, 2006.

By: *Arthur Bousier***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Application: Samy ASHKAR *et al.*

Confirmation No.: 6946

Application No.: 10/091,724

Group Art Unit: 1634

Filed: March 6, 2002

Examiner: Carla Myers

For: METHODS TO SCREEN PEPTIDE LIBRARIES USING MINICELL DISPLAY

VIA FACSIMILE
AFTER-FINAL COMMUNICATION
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Interview Summary

Applicants thank the Examiner for the Interview on May 10, 2006. At the Interview, the advantages of the claimed minicell display system were discussed. In particular, Applicants showed that it would not have been obvious to a skilled artisan to screen a peptide library by expressing a fusion protein comprising a fragment of the 17K antigen of *Rickettsia rickettsii* fused to a second peptide on the outer surface of a minicell.

The background section of the Huang *et al.* patent (U.S. Patent 5,516,637) cited by the Examiner teaches that past attempts to develop bacterial display methods by expressing a fusion protein containing a desired recombinant polypeptide fused to a native protein normally exposed on the cell's exterior have been largely unsuccessful. According to the reference, the foreign

PATENT
Application No.: 10/091,724
Attorney Docket SOPH-002/02US

protein frequently interferes with localization, and the resulting fusion protein is unable to reach the cell's surface. For instance, Huang *et al.* provide that the fusion protein may suffer from incorrect orientation such that the polypeptide of interest is oriented facing the periplasm of the cell.

In order to get around this problem, display systems have been developed using large outer membrane proteins such as the pilus protein described in the Huang *et al.* reference. However, as shown by Applicants, there are limitations as to the size and structure of polypeptides that can be successfully expressed on a cell membrane using these constructs.

Applicants discussed how a portion of the 17K antigen of *Rickettsia rickettsii* containing a signal sequence and a lipid modification site can be used in one embodiment of the invention to present a peptide effectively on the surface of a minicell. Applicants pointed out that this peptide differs from a fusion protein containing the entire 17K antigen as disclosed in Georgiou *et al.* patent (U.S. Patent 5,348,867). As discussed with the Examiner, fusion proteins containing the full 17K antigen do not properly localize on the outer surface of a bacterial minicell. For this reason, it would not have been obvious to a skilled artisan that an N-terminal fragment of the 17K antigen containing both a signal sequence and lipid modification site would be expressed and properly localized to the cell surface of a minicell. In order to expedite the withdrawal of the outstanding rejection under 35 U.S.C. § 103(a), Applicants proposed amending claim 1 to recite the subject matter of claim 13, *i.e.*, recite an N-terminal fragment of the 17K antigen consisting essentially of a signal sequence and lipid modification site as the first peptide of the fusion protein. Applicants agreed to use "consisting essentially of" language in claim 1 to disclaim the use of a fusion protein containing a full length 17K antigen as well as a fusion protein containing

PATENT

Application No.: 10/091,724

Attorney Docket SOPH-002/02US

an N-terminal fragment of a protein containing a signal sequence and lipid modification site other than the 17K antigen of *Rickettsia rickettsii*.

Except for issue fees payable under 37 CFR 1.18, the commissioner is hereby authorized by this paper to charge any additional fees during the pendency of this application including fees due under 37 CFR 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-1283. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 CFR 1.136(a)(3).


If the Examiner has any further questions relating to this Interview Summary or to the application in general, she is respectfully requested to contact the undersigned by telephone so that allowance of the present application may be expedited.

Dated: May 16, 2006

COOLEY GODWARD LLP
Customer No. 58249
875 15th Street, NW, Ste. 800
Washington, DC 20005
Tel: 202-842-7800

Respectfully submitted,
COOLEY GODWARD LLP

By:


Heather Boussios
Reg. No. 52,704